Christopher Desmond to Adalimumab
This is a "connection" page, showing publications Christopher Desmond has written about Adalimumab.
Connection Strength
0,040
-
Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort. Intern Med J. 2019 06; 49(6):753-760.
Score: 0,040